Enliven Therapeutics, Inc. - ELVN
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G | Vestal Point Capital, LP | 6.5% | 3,830,000 | View |
| Feb 17, 2026 | SCHEDULE 13G | Ryan Wilder | 6.5% | 3,830,000 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Venrock Healthcare Capital Partners III, L.P. | 5.4% | 3,226,331 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | VHCP Co-Investment Holdings III, LLC | 5.4% | 3,226,331 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Venrock Healthcare Capital Partners EG, L.P. | 5.4% | 3,226,331 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | VHCP Management III, LLC | 5.4% | 3,226,331 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | VHCP Management EG, LLC | 5.4% | 3,226,331 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Nimish Shah | 5.4% | 3,226,331 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Bong Y. Koh | 5.4% | 3,226,331 | View |
| Nov 05, 2025 | SCHEDULE 13G/A | FMR LLC | 13.3% | 7,870,219 | View |
| Nov 05, 2025 | SCHEDULE 13G/A | Abigail P. Johnson | 13.3% | 7,870,219 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.